

Correction to: *Salmonella Typhi* From Blood Cultures in the Democratic Republic of the Congo: A 10-Year Surveillance

Bieke Tack,^{1,2} Marie-France Phoba,^{3,4} Sandra Van Puyvelde,^{5,6} Lisette M Kalonji,^{3,4} Liselotte Hardy,¹ Barbara Barbé,¹ Marianne A B Van der Sande,^{7,8} Elise Monsieurs,^{9,10} Stijn Deborggraeve,⁵ Octavie Lunguya,^{3,4} Jan Jacobs,^{1,2}

¹Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp. ²Department of Microbiology and Immunology, KU Leuven, Belgium. ³Department of Microbiology, National Institute for Biomedical Research. ⁴Department of Microbiology, University Teaching Hospital, Kinshasa, Democratic Republic of the Congo, Antwerp, Belgium. ⁵Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. ⁶Wellcome Trust Sanger Institute, Hinxton, United Kingdom. ⁷Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. ⁸Julius Center for Health Sciences and Primary Care, Global Health Centre, Utrecht University, The Netherlands. ⁹Royal Museum for Central Africa, Tervuren. ¹⁰Department of Geography, University of Liège, Belgium.

In the original publication of this manuscript [Tack B, Phoba M, Puyvelde SV et al. *Salmonella Typhi* From Blood Cultures in the Democratic Republic of the Congo: A 10-Year Surveillance. Clin Infect Dis. Volume 68 Supplement 2; March 15 2019,

S130-S137. <https://doi.org/10.1093/cid/ciy1116>], the article's Supplementary Table 2, the study's list of sequenced isolates and their metadata, was missing. It is hosted with this notice for review, and the authors regret this error.

Sample Name	Sero-typing UTLIM	MLST ST	GENOTYPHI GENOTYPE	D87G	S83F	E466D	A119E	D538N	D87Y	S83Y	I471S	S464Y	NrSandra	Nrorigdbid	Provenance2906	Provincecd	original	AgeA	Année	CIFE1908
3525_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	3525_3	6134	KISANTU	BAS-CONGO	7	2011	.25	
3592_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	3592_3	6201	KISANTU	BAS-CONGO	23	2011	.25	
3632_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	3632_3	6241	KISANTU	BAS-CONGO	11	2011	.38	
3524_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	3524_3	6133	KISANTU	BAS-CONGO	36	2011	.38	
3808_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	3808_3	7556	KISANTU	BAS-CONGO	20	2011	.38	
3841_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	3841_3	7589	KISANTU	BAS-CONGO	42	2011	.19	
3872_3	Typhi	2	2.5.1	no	no	no	yes	no	no	no	no	no	3872_3	7620	KISANTU	BAS-CONGO	4	2011	.38	
3874_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	3874_3	0	KISANTU	BAS-CONGO	33	2011	.38	
4209_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	4209_3	7957	KISANTU	BAS-CONGO	13	2011	.38	
4343_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	4343_3	9079	KISANTU	BAS-CONGO	6	2011	.38	
4421_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	4421_3	9157	KISANTU	BAS-CONGO	21	2012	.38	
4441_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	4441_3	9177	KISANTU	BAS-CONGO	45	2012	.38	
22246_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	22246_3	2483	HSLK	KONGO CENTRAL	29	2017	.25	
4586_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	4586_3	9322	KISANTU	BAS-CONGO	30	2012	.38	
5273_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	5273_3	10567	KISANTU	BAS-CONGO	42	2012	.25	
5741	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	5741_3	11035	KISANTU	BAS-CONGO	3	2012	.38	
5893_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	5893_3	11187	KISANTU	BAS-CONGO	8	2012	.38	
5885_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	5885_3	11179	KISANTU	BAS-CONGO	6	2012	.38	
5918_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	5918_3	11212	KISANTU	BAS-CONGO	19	2012	.38	
5927_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	5927_3	11221	KISANTU	BAS-CONGO	19	2012	.38	
5867_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	5867_3	11161	KISANTU	BAS-CONGO	10	2012	.38	
2697_13	Typhi	2	2.1	no	no	no	no	no	yes	no	no	no	2697_13	12803	VDP	ORIENTALE	4	2013	0.19	
22271_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	22271_3	2508	HSLK	KONGO CENTRAL	24M	2017	.25	
6591_3	Typhi	2	2.5.1	no	no	yes	no	no	no	no	no	no	6591_3	13143	KISANTU	BAS-CONGO	5	2013	.064	
6637_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	6637_3	13189	KISANTU	BAS-CONGO	57	2013	.38	
6657_3	Enteritidis	2	2.5.1	no	yes	no	no	no	no	no	no	no	6657_3	13209	KISANTU	BAS-CONGO	7	2013	.38	
6976_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	6976_3	13627	KISANTU	BAS-CONGO	42	2013	.38	
7196_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	7196_3	13847	KISANTU	BAS-CONGO	6	2013	.38	
7217_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	7217_3	13868	KISANTU	BAS-CONGO	3	2013	.38	
22272_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	22272_3	2509	HSLK	KONGO CENTRAL	7	2017	0.38	
22320_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	22320_3	2557	HSLK	KONGO CENTRAL	35	2017	.25	
22323_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	22323_3	2560	HSLK	KONGO CENTRAL	ND	2017	.25	
10613_17	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	10613_17	3842	CUK	KINSHASA	27	2017	.094	
22545_3	Enteritidis	2	2.5.1	no	yes	no	no	no	no	no	no	no	22545_3	2782	HSLK	KONGO CENTRAL	46M	2017	.38	
22493_3	Enteritidis	2	2.5.1	no	yes	no	no	no	no	no	no	no	22493_3	2730	HSLK	KONGO CENTRAL	31	2017	.25	
23164_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	23164_3	3401	HSLK	KONGO CENTRAL	32	2017	.25	
6807_3	Typhi	2	2.5.1	no	no	no	no	no	no	no	no	yes	6807_3	13458	KISANTU	BAS-CONGO	6	2013	.19	
7569_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	7569_3	14220	KISANTU	BAS-CONGO	29	2013	.38	
7818_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	7818_3	14740	KISANTU	BAS-CONGO	6	2013	.38	
9202_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9202_14	366	MBANZA VELELAZS KINGASANI	KINSHASA	16	2014	.25	
9207_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9207_14	371	CS LONDOLOBE/ZS KINGASANI	KINSHASA	14	2014	.25	
9210_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9210_14	374	CS LONDOLOBE/ZS KINGASANI	KINSHASA	10	2014	.25	

Sample Name	Sero-typing UTLIM	MLST ST	GENOTYPHI GENOTYPE	D87G	S83F	E466D	A119E	D538N	D87Y	S83Y	I471S	S464Y	Nr-Sandra	Nrorigidbid	Provenance2906		Provincecboriginal	AgeA	Année	CIPE1908
															gyrA_8	gyrB_1				
9213_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9213_14	377	DOMICILE/ZS KINGASANI	KINSHASA	11	2014	.25	
9214_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9214_14	378	CS KIMBANGUISTE/ZS KINGASANI	KINSHASA	32	2014	.25	
9238_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9238_14	402	CS LONDOLLOBE/ZS KINGASANI	KINSHASA	44	2014	.25	
9262_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9262_14	426	CS LONDOLLOBE/ZS KINGASANI	KINSHASA	23	2014	.25	
9267_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9267_14	431	CS LONDOLLOBE/ZS KINGASANI	KINSHASA	12	2014	.25	
9305_14	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9305_14	469	HGR MOSANGO/ZS KINGASANI	KINSHASA	ND	2014	.38	
8357_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	8357_3	497	HSLK	BAS-CONGO	29M	2014	.094	
21602_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	21602_3	1707	HSLK	KONGO CENTRAL	8	2017	.38	
8375_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	8375_3	515	HSLK	BAS-CONGO	40	2014	.125	
8675_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	8675_3	815	HSLK	BAS-CONGO	27	2014	0.12	
9099_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	9099_3	1238	HSLK	BAS-CONGO	7	2014	.12	
8852_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	8852_3	992	HSLK	BAS-CONGO	23M	2014	.06	
9311_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	9311_3	1450	HSLK	BAS-CONGO	2	2014	.25	
9392_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9392_3	1531	HSLK	BAS-CONGO	10J	2014	.25	
9728_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	9728_3	2579	HSLK	BAS-CONGO	30	2014	.25	
10474_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	10474_3	4337	HSLK	BAS-CONGO	27M	2014	.12	
11280_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	11280_3	5143	HSLK	BAS-CONGO	ND	2014	.25	
12942_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	12942_3	6919	HSLK	BAS-CONGO	10	2015	.25	
9642_15	Typhi	2	2.5.1	no	no	no	no	no	no	yes	no	no	9642_15	7739	HGR BWAMANDA	EQUATEUR	28	2015	.125	
9921_15	Typhi	2	2.5.1	no	no	no	no	no	no	yes	no	no	9921_15	8887	HGR BWAMANDA	EQUATEUR	9	2015	.19	
14708_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	14708_3	9201	HSLK	BAS-CONGO	30	2015	.094	
14824_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	14824_3	9317	HSLK	BAS-CONGO	29	2015	.094	
14381_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	14381_3	8627	HSLK	BAS-CONGO	15	2015	.19	
13231_3	Typhi	2	2.5.1	no	no	no	no	no	no	yes	no	no	13231_3	7208	HSLK	BAS-CONGO	24	2015	.25	
15601_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	15601_3	10302	HSLK	BAS-CONGO	5	2015	.094	
15824_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	15824_3	10525	HSLK	BAS-CONGO	28	2016	.125	
16428_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	16428_3	11435	HSLK	BAS-CONGO	22	2016	.125	
16820_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	16820_3	11827	HSLK	BAS-CONGO	28	2016	.25	
17421_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	17421_3	12444	HSLK	KONGO CENTRAL	41	2016	.125	
10456_16	Typhi	1	4.3.1	no	no	no	yes	no	no	yes	no	no	10456_16	14150	CUK	EQUATEUR	22	2016	.25	
5706_4	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	5706_4	58	HGRK	TSHOPO	5	2017	.25	
18858_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	18858_3	14492	HSLK	KONGO CENTRAL	45	2016	.25	
20298_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	20298_3	403	HSLK	KONGO CENTRAL	7	2017	.25	
20304_3	Typhi	2	2.5.1	yes	no	no	no	no	no	no	no	no	20304_3	409	HSLK	KONGO CENTRAL	6	2017	.125	
20867_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	20867_3	972	HSLK	KONGO CENTRAL	5	2017	.38	
22066_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	22066_3	2303	HSLK	KONGO CENTRAL	10	2017	.25	
2228_09	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2228_09	547	CS MOBENGI	KINSHASA	9	2009	0.19	
3673	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	3673	661	CUK	KINSHASA	32	2009	0.25	
2267_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2267_3	1625	KISANTU	BAS-CONGO	15	2009	0.38	
2366	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2366_3	0	KISANTU	BAS-CONGO	40	2009	0.25	

Sample Name	Sero-typing UTLM	MLST ST	GENOTYPHI GENOTYPE	gyrA_8 D87G	gyrA_8 S83F	gyrB_1 E466D	gyrA_8 A119E	gyrA_8 D538N	D87Y	S83Y	gyrB_1 I471S	S464Y	NrSandra	NrorigdbID	Provenance2906	Provincedboriginal	AgeA	Année	CIPE1908
2539_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2539_3	3212	KISANTU	BAS-CONGO	30	2010	0.38
2628_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2628_3	3301	KISANTU	BAS-CONGO	17	2010	0.38
2654_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2654_3	3327	KISANTU	BAS-CONGO	5	2010	0.19
2656_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2656_3	3329	KISANTU	BAS-CONGO	6	2010	0.38
2052_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2052_3	931	KISANTU	BAS-CONGO	60	2009	0.25
2399_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2399_3	3072	KISANTU	BAS-CONGO	12	2009	0.38
2531_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2531_3	3204	KISANTU	BAS-CONGO	70	2010	0.38
2606_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2606_3	3279	KISANTU	BAS-CONGO	5	2010	0.25
2072_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2072_3	951	KISANTU	BAS-CONGO	19	2009	0.19
2557_3	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	2557_3	3230	KISANTU	BAS-CONGO	3	2010	0.38
10040_15	Typhi	2	2.5.1	no	yes	no	no	no	no	no	no	no	10040_15	9755	CSTAMBU-TSEKE/ DPS KIVANGO	BANDUNDU	6	2015	.38

<https://doi.org/10.1089/cid/ciac145>

CONFIDENCE IN DOVATO ACROSS TREATMENT SETTINGS⁴⁻⁹

Treatment-naïve resistance rates, with up to **3 years** of evidence⁵⁻⁷

0%
(n=0/1,885)^{*4}
REAL-WORLD EVIDENCE

0.1%
(n=1/953)^{**1,11,5,5-7}
RANDOMISED CONTROLLED TRIALS

Treatment-experienced resistance rates, with up to **5 years** of evidence¹⁻³

0.03%
(n=10/35,888)^{*4}
REAL-WORLD EVIDENCE

0%
(n=0/615)^{11,5,8,9}
RANDOMISED CONTROLLED TRIALS

>300,000 PEOPLE LIVING WITH HIV HAVE BEEN TREATED WITH DOVATO GLOBALLY¹⁰

DOVATO is supported by a wealth of evidence, with the outcomes of **>40,000** people living with HIV captured within clinical trials and real-world evidence, including those with:^{4-9,11,12}



NO PRIOR TREATMENT EXPERIENCE¹³



NO BASELINE RESISTANCE TESTING¹³




HIGH BASELINE VIRAL LOAD
(>100,000 copies/mL and even >1M copies/mL)^{6,13}



LOW CD4 + COUNT
(≤200 cells/mm³)¹³

■ Patients from phase III RCTs

■ Patients from unique real-world cohorts



IS IT TIME TO RECONSIDER THE VALUE OF THE 2ND NRTI?

LEARN MORE

DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.¹³

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221441

REFERENCES

- Maggiolo F et al. BMC Infect Dis 2022; 22(1): 782.
- Taramasso L et al. AIDS Patient Care STDS 2021; 35(9): 342-353.
- Ciccullo A et al. JAIDS 2021; 88(3): 234-237.
- ViiV Healthcare. Data on File. REF-223795. 2024.
- Cahn P et al. AIDS 2022; 36(1): 39-48.
- Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
- Cordova E et al. Poster presented at 12th IAS Conference on HIV Science. 23-26 July 2023. Brisbane, Australia. TUPEB02.
- De Wit S et al. Slides presented at HIV Glasgow. 23-26 October 2022. Virtual and Glasgow, UK. M041.
- Llibre J et al. Clin Infect Dis 2023; 76(4): 720-729.
- ViiV Healthcare. Data on File. REF-220949. 2024.
- Rolle C et al. Poster presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1603.
- Slim J et al. Abstract presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1593.
- DOVATO. Summary of Product Characteristics. June 2023.

PRESCRIBING INFORMATION

[Dovato Prescribing Information](#)

[Legal Notices](#)

[Privacy Policy](#)

[Contact Us](#)

ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, London, UK.

ViiV trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Non-ViiV trademarks are owned by or licensed to their respective owners or licensors.

©2024 ViiV Healthcare group of companies or its licensor. All rights reserved.

Intended for healthcare professionals only.

ABBREVIATIONS

3TC, lamivudine; **CD4**, cluster of differentiation 4; **DTG**, dolutegravir; **FDA**, United States Food and Drug Administration; **FTC**, emtricitabine; **HIV**, human immunodeficiency virus; **ITT-E**, intention-to-treat exposed; **NRTI**, nucleoside/nucleotide reverse transcriptase inhibitor; **RCT**, randomised controlled trial; **RNA**, ribonucleic acid; **TAF**, tenofovir alafenamide fumarate; **TDF**, tenofovir disoproxil fumarate; **XTC**, emtricitabine.

FOOTNOTES

*Data extracted from a systematic literature review of DTG+3TC real-world evidence. Overlap between cohorts cannot be fully excluded.

**The reported rate reflects the sum-total of resistance cases calculated from GEMINI I and II (n=1/716, through 144 weeks), STAT (n=0/131, through 52 weeks), and D2ARLING (n=0/106, through 24 weeks).⁵⁻⁷

†GEMINI I and II are two identical 148-week, phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority, controlled clinical trials testing the efficacy of DTG/3TC in treatment-naïve patients. Participants with screening HIV-1 RNA ≤500,000 copies/mL were randomised 1:1 to once-daily DTG/3TC (n=716, pooled) or DTG + TDF/FTC (n=717, pooled). The primary endpoint of each GEMINI study was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).¹³

‡STAT is a phase IIIb, open-label, 48-week, single-arm pilot study evaluating the feasibility, efficacy, and safety of DTG/3TC in 131 newly diagnosed HIV-1 infected adults as a first line regimen. The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 24.⁶

§D2ARLING is a randomised, open-label, phase IV study designed to assess the efficacy and safety of DTG/3TC in treatment-naïve people with HIV with no available baseline HIV-1 resistance testing. Participants were randomised in a 1:1 ratio to receive DTG/3TC (n=106) or DTG + TDF/XTC (n=108). The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48.⁷ Results at week 24 of the study.

|| The reported rate reflects the sum-total of resistance cases calculated from TANGO (n=0/369, through 196 weeks) and SALSA (n=0/246, through 48 weeks).^{8,9}

¶TANGO is a randomised, open-label, trial testing the efficacy of DOVATO in virologically suppressed patients. Participants were randomised in a 1:1 ratio to receive DOVATO (n=369) or continue with TAF-containing regimens (n=372) for up to 200 weeks. At Week 148, 298 of those on TAF-based regimens switched to DOVATO. The primary efficacy endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL (virologic non-response) as per the FDA Snapshot category at Week 48 (adjusted for randomisation stratification factor).^{8,13}

#SALSA is a phase III, randomised, open-label, non-inferiority clinical trial evaluating the efficacy and safety of switching to DTG/3TC compared with continuing current antiretroviral regimens in virologically suppressed adults with HIV. Eligible participants were randomised 1:1 to switch to once-daily DTG/3TC (n=246) or continue current antiretroviral regimens (n=247). The primary endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).⁹